Skip to main content
Premium Trial:

Request an Annual Quote

Quest Licenses Clinical Genomics' Biomarkers

NEW YORK (GenomeWeb News) – Quest Diagnostics has licensed Clinical Genomics' biomarkers associated with colorectal cancer in order to develop them as a detection tool, Clinical Genomics said today.

Under the two-year agreement, Clinical Genomics will receive milestone payments to allow Quest Diagnostics to develop the gene-based portfolio to detect precancerous and cancerous colorectal tumors. Quest's rights under the pact are worldwide and exclusive.

Quest Diagnostics also made an equity investment in Clinical Genomics of an undisclosed sum.

Quest Diagnostics in 2006 acquired Enterix, a maker of the Food and Drug Administration-cleared InSure fecal immunochemical test for aiding the detection of colorectal cancer based on stool testing. Clinical Genomics is a spinoff of Enterix.

Clinical Genomics said it discovered the markers through a collaboration with Flinders University of South Australia and the Australian Government's Commonwealth Scientific and Industrial Research Organization, and that they "show promise as aids in detection of both colorectal cancer and precancerous adenomas."

Further financial terms of the agreement were not released.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.